Mayo gave a presentation yesterday at the 31st annual San Antonio Breast Cancer Symposium that further confirms the importance of the liver enzyme CYP2D6 in tamoxifen effectiveness. Tamoxifen is often prescribed to block the effects of estrogen in breast tissue to prevent breast cancer recurrence in ER+ (estrogen receptor positive) cancers which require estrogen to [...]
Filed under: Cytochrome P450, Drug Interactions, Personalized Medicine, Pharmacogenetics | Tagged: breast cancer, CYP2D6, Cytochrome, genotyping, persoanlized medicine, tamoxifen | 1 Comment »
